IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA reported positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib, which met its primary endpoint by reducing the risk of disease progression by 58% in first-line HLA*A2-negative metastatic uveal melanoma. Based on these results, IDEAYA plans to initiate the FDA RTOR submission process in May with a target NDA filing in the second half of 2026, while maintaining a cash runway into 2030 with $973 million in cash and equivalents.
Key figures
- Drug Name
- darovasertib
- Phase Of Trial
- Phase 2/3
- Orr percent
- 37.1
- Hazard ratio
- 0.42
- Cash balance usd
- 972900000
- Cash runway year
- 2030
- Pfs months control
- 3.1
- Pfs months treatment
- 6.9
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.